Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Sponsor
Fudan University
Study ID
NCT04978012
Phase
PHASE2
Status
Unknown

Conditions

  • Nasopharyngeal Cancer
  • Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Fluzoparib and Camrelizumab — DRUG
    Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.

Study Details

The aim of this study is to define the efficacy and safety of Fluzoparib and Camrelizumab in treating patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after first-line chemotherapy.

Key Dates

Start date
Jul 25, 2021
Status verified
Jun 2022
Primary completion
Dec 31, 2024
Completion
Dec 31, 2025

Study Design

Enrollment
48 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Combination of Fluzoparib and Camrelizumab
    Fluzoparib,150mg bid po, d1-21, q3w Camrelizumab 200mg iv, d1, q3w

Primary Outcome Measure

Overall response rate [ Time Frame: Within 2 year post-treatment ]

Central Contacts

Related Studies